Drugs

ADA Advises Wider Use of Diabetes Medications

For its 2020 recommendations, the American Diabetes Association (ADA) is now advising doctors to consider prescribing sodium glucose co-transporter 2 (SGLT2) inhibitors or glucagon-like peptide 1 (GLP-1) receptor agonists to patients at high risk for heart failure or chronic kidney disease (CKD), not only in patients who already have the disease. Read more

Glucocorticoids May Increase Diabetes Risk

Glucocorticoids (GC) may expose patients to the risk of diabetes, particularly with long term use, a recent study suggests. Glucocorticoids are extensively used in almost every subspecialty of medicine to treat conditions like asthma, allergies, and even rheumatoid conditions. However, they have metabolic side effects like hypertension and have a direct impact on diabetes. Read […]

Antidepressant Medications Reduce Hyperglycemic Episodes

Adults who have both diabetes and depressive disorder and who were treated with antidepressant drugs experienced fewer episodes of hyperglycemic crisis than those who were not taking antidepressant medications, new research has found. Read more

Oral Insulin May Soon Be Reality

A Phase 2b study in patients with type 2 diabetes (T2DM) was completed for what looks likely to be the first oral form of insulin (ORMD-0801). The developing company, Oramed Pharmaceuticals’, CEO Nadav Kidron and Dr. Joel Neutel, Principal Investigator of the study discuss the results. Read more

Is Metformin Safe for those with Impaired Kidney Function?

A recent study investigated metformin vs. sulfonylureas in patients with reduced kidney function and diabetes regarding major adverse cardiovascular events (MACE). In the past, safety concerns over metformin use in kidney disease have limited its use. Read more

Weight Loss Drugs Rarely Prescribed to Eligible Patients

The authors of a new study which examined prescribing patterns in more than 2 million Americans from 2009 to 2015 found that weight-loss medications are rarely prescribed to eligible patients, despite the obesity epidemic. Read more

SGLT2 Inhibitors Associated with Rare Gangrene

Patients taking an SGLT2 inhibitor should be aware of the signs of Fournier gangrene, a rare but potentially life-threatening bacterial infection of the skin that involves the tissues, surrounding muscles, nerves, and blood vessels of the external genitalia, perianal region, and perineum (the area between the anus and scrotum for men; between the anus and […]

Does Metformin Have Anti-Cancer Properties?

There have been conflicting findings on the diabetes drug metformin’s possible relationship to cancer.  The majority of studies conducted on metformin or other glucose-lowering medications and their effect on cancer risk have found inconclusive results, but some research suggests metformin may have a beneficial role in certain types of cancer. Read more

Breast Cancer Drug May Help Type 1 Diabetes

A drug used to treat breast cancer, neratinib, has the potential to stop the immune system from destroying beta cells in type 1 diabetes, according to German researchers. The researchers found that Neratinib was able to protect the beta cells, which produce insulin in the pancreas, enabling the beta cells to continue to produce insulin. […]

Canagliflozin Not a Fracture Risk After All?

In recent years, there have been warnings for the use of SGLT-2 Inhibitors that suggest an increased risk of fracture, particularly when placed on one SGLT2 inhibitor, canagliflozin (Invokana). In 2015, the US FDA added a warning on canagliflozin, indicating that patients on canagliflozin must use caution because of a fracture risk associated with the […]

New Trial for Combination Therapy

The TTT-1 trial will begin in Scotland early in 2020 to assess a new combination therapy using insulin, dapagliflozin, and semaglutide. It is being led by Dr John Petrie from the University of Glasgow, a leading expert in the treatment of type 1 diabetes. The trial hopes the treatment will become a new option for […]

New Once-Daily Diabetes Pill

Qternmet XR is a single, once daily oral tablet made of dapagliflozin, saxagliptin, and metformin. Results show that the combination of dapagliflozin and saxagliptin have improved glycemic outcomes when added to metformin in patients with diabetes as compared to either drug alone added to metformin. Adverse effects are similar to those of the individual medications. […]

First Oral GLP-1 For Type 2 Diabetes: Rybelsus

Oral semaglutide, brand name Rybelsus, is the first GLP-1 agonist that can be taken by mouth rather than requiring an injection. Studies have shown a significant reduction in A1c, a reduction in cardiovascular disease, and a reduction in weight, without the risk of hypoglycemia, for this drug. Patients must carefully follow instructions for taking the […]

FDA Approval of Invokana for Kidney Disease “First Major Breakthrough in 20 Years”

The FDA has approved a new treatment of Invokana for diabetic chronic kidney disease (CKD), which affects one in three patients with type 2 diabetes. CKD increases the risk for serious cardiovascular events and end-stage renal disease in patiens with type 2 diabetes. The approval of Invokana meets a 20 year need for therapy to […]

Type 1 Cannabis Users at Greater Risk for Ketoacidosis

Adults with type 1 diabetes who use cannabis products are more than twice as likely to develop diabetic ketoacidosis as non-cannabis users with type 1, according to a recent study. The researchers say increased appetite due to cannabis use may be a factor, along with impaired ability to manage diabetes. Read more

FDA Approves New Indication for Invokana

The FDA has approved a new treatment of the diabetes drug Invokana for diabetic kidney disease, which affects one in three patients with type 2 diabetes and increases the risk for serious cardiovascular issues and kidney failure. Read more

Liraglutide and Gall Bladder Issues

In addition to glycemic control, liraglutide also promotes weight loss, which can be helpful in patients with obesity and type 2 diabetes. However, development of gallstones may be a common side effect in patients that are on liraglutide for the treatment of their type 2 diabetes. Read more

FDA Approves Oral Semaglutide for Type 2 Diabetes

The U.S. Food and Drug Administration (FDA) has approved a new medication, Rybelsus (semaglutide) oral tablets, for use in controlling blood sugar in adults with type 2 diabetes, along with diet and exercise. Rybelsus is the first medication in the glucagon-like peptide (GLP-1) receptor class that does not need to be injected to be approved […]

Two Diabetes Drugs Show Benefits for Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) often occurs in patients with type 2 diabetes. A recent study showed that the diabetes medications liraglutide and sitagliptin, in combination with metformin, can improve intrahepatic lipid and therefore benefit NAFLD. Read more

Metformin Lowers Risk of Dementia for Black Patients

Researchers found that metformin use was associated with a substantially lower risk for dementia among younger African-American patients with diabetes when compared with sulfonylurea, according to a recently published study. Read more